ClinicalTrials.gg
RecruitingNCT07052929Updated Nov 9, 2026

Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators

A Phase 1/2 interventional study of ASP2957 and Methylprednisolone in X-Linked Myotubular Myopathy, sponsored by Astellas Gene Therapies. Recruiting at 5 sites in 2 countries. Open to male participants aged Up to 36 Months. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Astellas Gene Therapies (part of Astellas Pharma Inc) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
Up to 36 Months
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Myopathies, Structural, Congenital with a site in United States — 4 open to participants now, 6 under way, 1 of them phase 3. Myopathies, Structural, Congenital · United States.

Started
2025
with 2 others
Phase 1/2
2 of 13
1 open now
Registered
11th of 13
by date
Lead sponsor
5 of 13
Astellas Gene Therapies

Among the 13 studies in Myopathies, Structural, Congenital with a site in United States, this one is one of 3 that started in 2025, is one of 2 in phase 1/2, and was the 11th registered.

Myopathies, Structural, Congenital

24 studies on the registry are indexed under Myopathies, Structural, Congenital; 10 are open to participants now.

Browse Myopathies, Structural, Congenital studies →

Open to participants now

4 of the 13 studies in Myopathies, Structural, Congenital with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Myopathies, Structural, Congenital studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: Up to 36 Months · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Myopathies, Structural, Congenital with a site in United States, or all of them as a file.
02

Study summary

X-linked myotubular myopathy (XLMTM) is a rare and serious condition present at birth where the muscles do not work properly. There are currently no approved therapies for XLMTM.

The protein myotubularin is needed for muscle development, movement and breathing. A gene called MTM1 tells the body to make myotubularin. XLMTM is caused by changes, or mutations, in the MTM1 gene. Changes in the MTM1 gene cause low or no levels of myotubularin to be made, so the muscles do not work properly.

Gene therapy is a way of getting a healthy copy of a gene into the body. This allows the body's cells to make a normal protein that may reduce disease symptoms. Researchers have developed ASP2957 to get a healthy MTM1 gene into the body. This could help improve muscle development and function in young children with XLMTM.

In this study, ASP2957 will be given to humans for the first time.

ASP2957 has the healthy MTM1 gene inside a type of empty (killed) virus. The virus delivers the healthy MTM1 gene directly into cells in the body. It's possible that some boys may have antibodies to the virus if they have previously been infected with a similar virus. The antibodies could stop ASP2957 from working properly and cause an immune reaction to ASP2957. To prevent this, the boys will also be given medicines to lower the immune system.

The main aims of this study are to check the safety of ASP2957, how well it is tolerated, and to find a suitable dose of ASP2957.

The study was designed in 2 phases. In Phase 1, different small groups of boys will receive lower to higher doses of ASP2957. Each boy will receive a single infusion of ASP2957. Any medical problems will be recorded for each dose. This is done to find a suitable dose of ASP2957 to use in Phase 2.

In Phase 2, another small group of young boys will receive a single infusion of ASP2957. The most suitable dose of ASP2957 worked out from Phase 1 will be used.

The boys will be checked for up to 1 year after their single infusion of ASP2957. After this, there will be the option for the boys to join another study so they will continue to be checked longer term.

03

Conditions studied

  • X-Linked Myotubular Myopathy

Keywords

  • XLMTM
  • Recombinant Adeno-Associated Virus
04

Who can participate

Ages eligible
Up to 36 Months
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is projected to be ≤ 36 months of age at dosing.
  • Participant has molecular genetic report from a CAP-approved testing facility at screening that confirms a diagnosis of XLMTM and harbors a "pathogenic" or "likely pathogenic" variant in the MTM1 gene as classified using the American College of Medical Genetics (ACMG) standards and guidelines for interpretation of sequence variants. Although samples will be sent to the sponsor central laboratory during screening for exploratory testing, results of this testing are not required for enrollment.
  • Participant is ventilator-dependent and meets the following criteria:

    • Required respiratory support at birth
    • Requires ≥ 20 hours per day of invasive ventilator support (confirmed during screening)
    • Has a tracheostomy tube
  • Participant has no evidence of hepatic peliosis, increased echogenicity or any other abnormal finding on liver ultrasound.
  • Participant can receive per protocol.
  • Participant's hepatobiliary laboratory measurements must meet the criteria during screening and for the 2-month retrospective assessment of participant's medical history from the time of signing the ICF:
  • Participant's hematological laboratory measurements must meet the criteria during screening:
  • Participant's parent(s) or legally authorized representative LAR(s) must provide documentation of being current with recommended immunization schedule according to regional guidelines.

    • If any immunization has not been administered, the medical reasons must be documented by the investigator along with medical risk associated with ASP2957 and immunosuppression administration. The sponsor will review the risk assessment with the investigator and determine the participant's eligibility for the study.
    • Immunizations requiring administration after inclusion in the study must be administered in accordance with regional guidelines for live, live attenuated and inactivated immunization prior to, during and after stopping immunosuppression with methylprednisolone, prednisolone and sirolimus. For an example of guidelines, see Centers for Disease Control and Prevention (CDC) General Best Practices Guidelines for Immunization.
    • Immunization of household contacts can be considered based on regional standards of care of individuals receiving immunosuppression regimens.
  • Participant and participant's parent(s) or LAR(s) are willing and able to comply with study visits and study procedures.
  • Participant's parent(s) or LAR(s) agree that the participant will not participate in another interventional study from the time of signing the Form (ICF) through week 52.
  • Participant's parent(s) or LAR(s) is willing to transition the participant to a separate long-term follow-up study after study completion.

Exclusion criteria

Exclusion Criteria:

  • Participant born \< 35 weeks gestation is still not term as per corrected age.
  • Participant is nutritionally unstable with weight less than fifth percentile for age or has a vitamin A, E or K deficiency.
  • Participant requires supplemental oxygen on a routine or chronic basis.

    • Note: The use of supplemental oxygen for acute, self-limited illnesses (for example, during hospitalization for pneumonia) shall not be exclusionary, provided the participant is neither acutely ill nor using supplemental oxygen at the time of screening.
  • Participant currently has a respiratory infection or other clinically important active infection of any kind.
  • Participant has an active viral or bacterial infection including, but not limited to, positive testing for the following:

    • tuberculosis (TB) using the QuantiFERON-TB test
    • Active hepatitis A virus (HAV), virus (HBV) or virus (HCV)
    • Prior HBV or HCV virus infection due to the risk of reactivation associated with
    • type 1 (HIV-1) and human immunodeficiency virus type 2 (HIV-2)
    • coronavirus disease 2019 (COVID-19)
    • cytomegalovirus (CMV), viral loads ≥ 500 IU/mL or attributable symptoms or evidence of end-organ disease due to CMV.
  • Participant has any history of cholestatic liver dysfunction and/or treatment for cholestasis. If the participant is taking prophylactic treatment for cholestasis (e.g., ursodiol, cholestyramine, rifampin or other therapies) which has not been prescribed for cholestatic liver dysfunction, treatment must be discontinued for at least 4 weeks prior to signing the ICF.

    • Neonatal hyperbilirubinemia resolving within 4 weeks of birth in a full-term infant is not an exclusion.
  • Participant has prior history of abnormal transaminases ( (ALT) or aspartate aminotransferase (AST)) and/or abnormal metabolism associated with ascites, jaundice (aside from neonatal hyperbilirubinemia) or gastrointestinal bleeding.
  • Participant has a significant medical condition or life-threatening disease other than XLMTM that would interfere with adhering to protocol requirements or would increase the risk of immunosuppression and/or recombinant adeno-associated virus (rAAV) administration.
  • Participant has musculoskeletal complications such as severe contractures and/or scoliosis that would limit the ability to observe improvements in neuromuscular function.

    • In participants with scoliosis, the Cobb angle must be \< 40 degrees for study eligibility.
  • Other than as required per protocol, participant has received or plans to receive systemic immunomodulating agents within 90 days before day 1 (use of inhaled to manage chronic respiratory conditions is allowed).
  • Participant has previously received monoclonal antibodies of any type.

    • Exception: Monoclonal antibodies to prevent RSV are permitted, except for during the 4 weeks prior to the initiation of immunosuppression.
  • Participant plans to have surgery within 12 weeks prior to day 1 through week 52 that may confound safety and efficacy data interpretation of the study intervention.

    • Exception: Standard of care surgical interventions such as gastrostomy, jejunostomy and Nissen fundoplication procedures are allowed.
  • Participant received any treatment for cholestasis (e.g., ursodiol, cholestyramine, rifampin or other therapies) prior to signing the ICF.
  • Participant is participating in another interventional study or has received an adeno-associated virus (AAV)-based gene therapy.
  • Participant tests positive for anti-MyoAAV3.8 TAb, as determined by central laboratory testing.

    • Since very young children may have passive antibodies transferred in utero from the mother, participants ≤ 6 months of age who initially test positive for anti-MyoAAV3.8 total antibody (TAb) may be rescreened for study eligibility.
  • Participant has a known or suspected or to methylprednisolone, prednisolone, sirolimus or any components of the ASP2957 formulation.
  • Participant has a contraindication to general anesthesia, magnetic resonance imaging (MRI) or muscle procedures.
  • Any other reason that would render the participant unsuitable for participation in the study, including risk of non-adherence to the study assessments and protocol.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    Part 1 : ASP2957 Dose Escalation

    Participants will receive sequential dose levels of a single infusion of ASP2957 and immunosuppression prophylaxis including methylprednisolone, prednisolone and sirolimus.

    Genetic: ASP2957 · Drug: Methylprednisolone · Drug: Prednisolone · Drug: Sirolimus

  • Experimental
    Part 2: ASP2957 Dose Expansion

    Participants will receive a single infusion of ASP2957 (dose selected in Part 1) and immunosuppression prophylaxis including methylprednisolone, prednisolone and sirolimus.

    Genetic: ASP2957 · Drug: Methylprednisolone · Drug: Prednisolone · Drug: Sirolimus

Interventions

  • GeneticASP2957

    Intravenous infusion

    Also known as: MyoAAV3.8 engineered capsid - myosin heavy chain kinase 7 - human myotubularin (MyoAAV3.8-MHCK7-hMTM1)

  • Intravenous infusion

  • Route of administration based on locally sourced product

  • Route of administration based on locally sourced product

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment emergent adverse events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of study intervention. This includes events related to the comparator, if applicable, and events related to the (study) procedures. A TEAE is defined as an AE observed after administration of ASP2957.

    Time frame: Up to week 52

  2. Number of participants with adverse events of special interest (AESIs)

    AESIs include myocardial-associated events, muscle abnormalities, hepatobiliary disorders, thrombocytopenia, TMA and life-threatening infections.

    Time frame: Up to week 52

  3. Number of participants with laboratory value abnormalities and/or adverse events (AEs)

    Number of participants with potentially clinically significant laboratory values.

    Time frame: Up to 52 weeks

  4. Number of participants with electrocardiogram (ECG) abnormalities and/or AEs

    Number of participants with potentially clinically significant ECGs.

    Time frame: Up to 52 weeks

  5. Number of participants with echocardiogram (ECHO) abnormalities and/or AEs

    Number of participants with potentially clinically significant ECHOs.

    Time frame: Up to 52 weeks

  6. Number of participants with muscle magnetic resonance imaging (MRI) abnormalities and/or AEs

    Number of participants with potentially clinically significant muscle MRIs.

    Time frame: Up to 52 weeks

  7. Number of participants with histopathology abnormalities and/or AEs from muscle biopsy

    Number of participants with potentially clinically significant histopathology from muscle biopsy.

    Time frame: Up to 52 weeks

  8. Number of participants with physical examinations abnormalities and/or AEs

    Number of participants with potentially clinically significant physical examinations.

    Time frame: Up to 52 weeks

Secondary outcomes

  1. Change from baseline in hours per day of ventilation support at week 52

    The hours of ventilation support will be collected.

    Time frame: Baseline and up to week 52

  2. ASP2957 vector deoxyribonucleic acid (DNA) in serum through week 52

    ASP2957 vector DNA will be recorded from serum samples collected.

    Time frame: Up to week 52

  3. ASP2957 vector DNA in muscle biopsy at week 52

    ASP2957 vector DNA will be recorded from muscle biopsy collected.

    Time frame: Week 52

  4. ASP2957 vector DNA in saliva

    ASP2957 vector DNA will be recorded from saliva samples collected.

    Time frame: Up to week 52

  5. ASP2957 vector DNA in urine

    ASP2957 vector DNA will be recorded from urine samples collected.

    Time frame: Up to week 52

  6. ASP2957 vector DNA in stool

    ASP2957 vector DNA will be recorded from stool samples collected.

    Time frame: Up to week 52

  7. Anti-MyoAAV3.8 total antibody (TAb)

    Anti-MyoAAV3.8 TAb will be recorded from serum samples collected

    Time frame: Up to week 52

  8. Anti-MyoAAV3.8 neutralizing antibody (NAb)

    Anti-MyoAAV3.8 NAb will be recorded from serum samples collected.

    Time frame: Up to week 52

  9. Anti-myotubularin TAb

    Anti-myotubularin TAb will be recorded from serum samples collected.

    Time frame: Up to week 52

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Oct 2027, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2025
First posted
Jul 8, 2025
StartActual
Dec 15, 2025
Primary completionEst.
Oct 31, 2027
CompletionEst.
Oct 31, 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07052929
Responsible party
Sponsor
First posted
Jul 8, 2025
Start date
Dec 15, 2025
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Astellas Gene Therapies
Contact
Astellas.registration@astellas.com
800-888-7704
Medical Director
study director · Astellas Gene Therapies

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Methylprednisolone · Prednisolone · Sirolimus

Start the discussion